SCHEMBL31064628

SCHEMBL31064628

CC(NC1CCC1)c1ccc(C2CC2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
S1PR3 Q99500 2/20 0.39
CACNA1G O43497 1/20 0.38
CACNA1H O95180 1/20 0.38
CACNA1I Q9P0X4 1/20 0.38
ACACB O00763 8/20 0.36
KDM4E B2RXH2 1/20 0.35
GLA P06280 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HIF1A Q16665 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CYP2D6 P10635 1/20 0.33
CYP11B2 P19099 1/20 0.33
NTRK1 P04629 2/20 0.32
GPR55 Q9Y2T6 1/20 0.32
NAMPT P43490 1/20 0.32
PPARG P37231 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24496044 0.77 KDM4E (0.44) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL31064696 0.77 CACNA1G (0.41) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL14242977 0.77 CHRNA7 (0.43) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL14580442 0.74 KDM4E (0.47) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL23005924 0.74 S1PR3 (0.41) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL25298245 0.74 S1PR3 (0.41) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL30521362 0.74 S1PR3 (0.41) L3MBTL1S1PR3CACNA1GCACNA1HCACNA1I
SCHEMBL28472061 0.73 GAA (0.53) L3MBTL1GAASMN1; SMN2
SCHEMBL31064441 0.72 S1PR1 (0.39) L3MBTL1GAAS1PR3ACACBGPR55
SCHEMBL11951665 0.72 KDM4E (0.50) L3MBTL1S1PR3KDM4EGLAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4688785-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-D] PYRROLO [3, 2-B] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 Beone Medicines I GmbH (CH) 2026-02-11 EP disclosed
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-11-07 US disclosed
WO-2024199255-A1 5-AMINO-6, 8-DIHYDRO-1H-FURO [3, 4-d] PYRROLO [3, 2-b] PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368177-A1 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 PRMT5, PRMT6, PRMT1 L3MBTL1 411/4885GAA 3919/4885S1PR3 3423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.